Historique
![Turning down the spice: tackling the problems of synthetic cannabinoids [Editorial]](https://bdoc.ofdt.fr/img_cache/pmb_ofdt_record_86303.webp?v=1771272115)
Article de Périodique
Turning down the spice: tackling the problems of synthetic cannabinoids [Editorial] (2023)
Auteur(s) :
SKUMLIEN, M. ;
CRAFT, S. ;
SCOTT, J. ;
FREEMAN, T. P.
Année
2023
Page(s) :
art. e076611
Sous-type de document :
Editorial
Langue(s) :
Anglais
Refs biblio. :
17
Domaine :
Drogues illicites / Illicit drugs
Discipline :
SAN (Santé publique / Public health)
Thésaurus géographique
ROYAUME-UNI
;
INTERNATIONAL
Thésaurus mots-clés
CANNABINOIDES
;
DROGUES DE SYNTHESE
;
LEGISLATION
;
REDUCTION DES RISQUES ET DES DOMMAGES
;
LUTTE
;
POLITIQUE
Résumé :
National and international policies are key to reducing use and harm
Synthetic cannabinoids, colloquially known as "spice," are a class of structurally diverse novel psychoactive substances that were originally designed to mimic the effects of Delta9-tetrahydrocannabinol, the main psychoactive compound in cannabis. In 2022, the European Monitoring Centre for Drugs and Drug Addiction was monitoring 224 synthetic cannabinoids, with new variations emerging every year. These drugs can produce strong effects at low doses, with potential for serious harms such as addiction and withdrawal, psychosis, seizure, cardiorespiratory problems, and death. Despite this, little is known about how their use can be managed in healthcare settings. [Extract]
Synthetic cannabinoids, colloquially known as "spice," are a class of structurally diverse novel psychoactive substances that were originally designed to mimic the effects of Delta9-tetrahydrocannabinol, the main psychoactive compound in cannabis. In 2022, the European Monitoring Centre for Drugs and Drug Addiction was monitoring 224 synthetic cannabinoids, with new variations emerging every year. These drugs can produce strong effects at low doses, with potential for serious harms such as addiction and withdrawal, psychosis, seizure, cardiorespiratory problems, and death. Despite this, little is known about how their use can be managed in healthcare settings. [Extract]
Affiliation :
Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK
Bristol Medical School, University of Bristol, Bristol, UK
Bristol Medical School, University of Bristol, Bristol, UK